Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment

ConclusionsAberrant activation of multiple pathways and low baseline tumor-infiltrating B cells are related to HER2  + BC trastuzumab-based recurrence, which primarily affects the antitumor activity of trastuzumab.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research